Among the most successful fund investment fields, there are Health Care, Medical Device. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight IMACTIS.
The usual cause for the fund is to invest in rounds with 6 partakers. The meaningful sponsors for the fund in investment in the same round are Medevice, M Capital Partners, Cru00e9dit Agricole Alpes Development.
The fund is constantly included in less than 2 deals per year. Deals in the range of 1 - 5 millions dollars are the general things for fund. The top activity for fund was in 2017.
| Fund Name | Location |
| Aztiq Pharma | Gullbringusysla, Iceland, Reykjavík |
| Caloga | France, Ile-de-France, Paris |
| Caufield Angel Fund | - |
| China-ASEAN etst Investment Cooperation Fund | China, Hong Kong, Hong Kong Island |
| Fremont Ventures | California, San Francisco, United States |
| Greenfield Cities Holdings, L.P. | - |
| iBuy | Australia, Melbourne, Victoria |
| IEG Venture Partners | Chicago, Illinois, United States |
| Ivy Capital Partners | Montvale, New Jersey, United States |
| Japan Post Investment | Chiyoda, Japan |
| Plastilin | - |
| Reinvent VC | Israel, Tel Aviv, Tel Aviv District |
| SBICAP Securities | India, Maharashtra, Mumbai |
| Suzhou Aerfa Investment Management Center | China, Jiangsu, Suzhou |
| The Aria Group | China, Hong Kong, Hong Kong Island |
| WaterBridge Ventures | Delhi, India, New Delhi |
| Wolsey Ventures | Genoa, Italy, Liguria |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
IMACTIS | $3M | 28 Nov 2017 | France, Auvergne-Rhône-Alpes, France |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
IMACTIS | $3M | 28 Nov 2017 | France, Auvergne-Rhône-Alpes, France |
